Baloxavir Marboxil's guest appearances

Baloxavir Marboxil

The Rounds Table

Emergency Medical Minute

Takotsubo Cardiomyopathy

Emily Hughes

James Lind

Peanut Placebo

Samir Grover

Kieran Quinn

Lupus Myocarditis

Lisa Raville

Alcoholic Ketoacidosis

Behcet Disease

Alexis St

Exotic Urticaria

Katie Bakes

Pete Bakes

Vivek Tayal

OwlTail

Contributor: Rachael Duncan, PharmD BCPS Educational Pearls:   According to the Department of Public Health and Environment who puts out a weekly report on the influenza virus in Colorado, there appears to be less influenza in Colorado than previous years  A milder influenza outbreak is likely due to mask wearing and social distancing practices  There have only been 22 hospitalizations for influenza in Colorado since the start of the flu season back in September and 0 outbreaks in long-term care facilities  Xofluza (baloxavir marboxil) is an antiviral PA endonuclease inhibitor and was approved by the FDA in 2018 for uncomplicated influenza in patients 12 years and older that have been symptomatic for less than 48 hours Patient’s getting Xofluza must be otherwise healthy or at risk of developing influenza-related complications  Due to limited data, Xofluza would not be a good option for those that are inpatient or critically ill and is best utilized for patients who are being seen in the emergency department and will be sent home  Currently Xofluza is not approved for complicated patients, pregnant patients or those that are breast-feeding which limits its use  When compared with Tamiflu in phase 3 studies, Xofluza was superior to placebo and similar to Tamiflu in shortening the duration of illness  Xofluza is a single dose that is weight based and appears to be very well tolerated with some adverse effects including headache, nausea and diarrhea   Xofluza showed a quicker recovery compared to Tamiflu by 8 hours which could be related to its one-time dosing  Cost is a limiting factor for the use of Xofluza. Tamiflu costs around $25 where as Xofluza (only available as brand name currently) is $156 at the cheapest  Pharmacists are still encouraging everyone to get their influenza vaccines despite less influenza cases this year   References:  Cdphe.colorado.gov. 2021. Influenza (flu) | Department of Public Health &amp; Environment. [online] Available at:  [Accessed 11 February 2021]. Ison, M., Portsmouth, S., Yoshida, Y., Shishido, T., Mitchener, M., Tsuchiya, K., Uehara, T. and Hayden, F., 2020. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 20(10), pp.1204-1214. Hayden, F., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M., Hurt, A., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., Kawaguchi, K., Shishido, T., Arai, M., Tsuchiya, K., Uehara, T. and Watanabe, A., 2018. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379(10), pp.913-923. Summarized by Emily Mack OMSIII   The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at www.emergencymedicalminute.com/cme-courses/ and create an account.

Contributor: Rachael Duncan, PharmD BCPS Educational Pearls:  <ul> <li>According to the Department of Public Health and Environment who puts out a weekly report on the influenza virus in Colorado, there appears to be less influenza in Colorado than previous years </li> <li>A milder influenza outbreak is likely due to mask wearing and social distancing practices </li> <li>There have only been 22 hospitalizations for influenza in Colorado since the start of the flu season back in September and 0 outbreaks in long-term care facilities </li> <li>Xofluza (baloxavir marboxil) is an antiviral PA endonuclease inhibitor and was approved by the FDA in 2018 for uncomplicated influenza in patients 12 years and older that have been symptomatic for less than 48 hours</li> <li>Patient’s getting Xofluza must be otherwise healthy or at risk of developing influenza-related complications </li> <li>Due to limited data, Xofluza would not be a good option for those that are inpatient or critically ill and is best utilized for patients who are being seen in the emergency department and will be sent home </li> <li>Currently Xofluza is not approved for complicated patients, pregnant patients or those that are breast-feeding which limits its use </li> <li>When compared with Tamiflu in phase 3 studies, Xofluza was superior to placebo and similar to Tamiflu in shortening the duration of illness </li> <li>Xofluza is a single dose that is weight based and appears to be very well tolerated with some adverse effects including headache, nausea and diarrhea  </li> <li>Xofluza showed a quicker recovery compared to Tamiflu by 8 hours which could be related to its one-time dosing </li> <li>Cost is a limiting factor for the use of Xofluza. Tamiflu costs around $25 where as Xofluza (only available as brand name currently) is $156 at the cheapest </li> <li>Pharmacists are still encouraging everyone to get their influenza vaccines despite less influenza cases this year </li> </ul> References:  <a href="http://Cdphe.colorado.gov" rel="nofollow" target="_blank">Cdphe.colorado.gov</a>. 2021. Influenza (flu) | Department of Public Health &amp; Environment. [online] Available at: [Accessed 11 February 2021]. Ison, M., Portsmouth, S., Yoshida, Y., Shishido, T., Mitchener, M., Tsuchiya, K., Uehara, T. and Hayden, F., 2020. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 20(10), pp.1204-1214. Hayden, F., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M., Hurt, A., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., Kawaguchi, K., Shishido, T., Arai, M., Tsuchiya, K., Uehara, T. and Watanabe, A., 2018. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379(10), pp.913-923. Summarized by Emily Mack OMSIII The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at <a href="http://www.emergencymedicalminute.com/cme-courses" rel="nofollow" target="_blank">www.emergencymedicalminute.com/cme-courses/</a> and create an account.

Pharmacy Phriday #9: Xofluza (Baloxavir marboxil) for Influenza

Andre Maddison, General Internal Medicine (GIM) fellow at Western University, is hosting this week’s episode on The Rounds Table alongside Mike Nicholson, clinical fellow in cystic fibrosis at the University of Toronto. Together they are covering antibiotic prophylaxis and incidence of infective endocarditis and baloxavir marboxil for uncomplicated influenza. Influenza viruses are emerging resistance to current treatments.  First, Mike covers an article on a new antiviral therapy, baloxavir marboxil that was studied in both a phase 2 and phase 3 trial.  Researchers were assessing whether this antiviral is safe for uncomplicated influenza in adults and adolescents compared to placebo and oseltamivir.  The researchers also reported on symptom relief and virologic endpoints. Antibiotic prophylaxis for infective endocarditis remains unclear.  The American Heart Association released guidelines for prescribing antibiotic prophylaxis for infective endocarditis in 2007.  Andre covers a study on the data of antibiotic prophylaxis and admissions for infective endocarditis after release of these guidelines. Next, the Good Stuff segment.  Mike highlights an article on patient with cystic fibrosis and their experience with a new gene-modulating drug.  Andre covers high-yield tips for management of patients with heart failure to address challenges that may be experienced by palliative care specialists. Finally, we have our first special segment of this year.  Sheliza and Emily interview Dr. Shelly Dev, critical care specialist at Sunnybrook Health Sciences Centre, on burnout in medicine. Like what you hear?  Rate us on iTunes!  Chat with us on Twitter at @roundstable and tweet at Mike Nicholson @doc_iron_mike. Interested in helping us evaluate our podcast episodes? We’re currently recruiting a panel of residents to serve as regular reviewers for the show. If you’re interested, email wkwong@qmed.ca. The Papers 1. Antibiotic Prophylaxis for IE: http://www.onlinejacc.org/content/72/20/2443 2. Baloxavir Marboxil: https://www.nejm.org/doi/full/10.1056/NEJMoa1716197 Good Stuff 1. Top Ten: https://www.liebertpub.com/doi/abs/10.1089/jpm.2018.0453?journalCode=jpm 2. Cystic Fibrosis: https://www.cbc.ca/news/canada/london/cystic-fibrosis-patient-london-orkambi-1.4864042 Music Credits The Rounds Table Theme Music by Brendan Quinn, Creative Director and Composer, Vapor RMW The post Quit Buggin’ Me: Antibiotic Prophylaxis for Infective Endocarditis and Baloxavir Marboxil for Uncomplicated Influenza appeared first on Healthy Debate.

Andre Maddison, General Internal Medicine (GIM) fellow at Western University, is hosting this week’s episode on The Rounds Table alongside Mike Nicholson, clinical fellow in cystic fibrosis at the University of Toronto. Together they are covering antibiotic prophylaxis and incidence of infective endocarditis and baloxavir marboxil for uncomplicated influenza. Influenza viruses are emerging resistance to current treatments.  First, Mike covers an article on a new antiviral therapy, baloxavir marboxil that was studied in both a phase 2 and phase 3 trial.  Researchers were assessing whether this antiviral is safe for uncomplicated influenza in adults and adolescents compared to placebo and oseltamivir.  The researchers also reported on symptom relief and virologic endpoints. Antibiotic prophylaxis for infective endocarditis remains unclear.  The American Heart Association released guidelines for prescribing antibiotic prophylaxis for infective endocarditis in 2007.  Andre covers a study on the data of antibiotic prophylaxis and admissions for infective endocarditis after release of these guidelines. Next, the Good Stuff segment.  Mike highlights an article on patient with cystic fibrosis and their experience with a new gene-modulating drug.  Andre covers high-yield tips for management of patients with heart failure to address challenges that may be experienced by palliative care specialists. Finally, we have our first special segment of this year.  Sheliza and Emily interview Dr. Shelly Dev, critical care specialist at Sunnybrook Health Sciences Centre, on burnout in medicine. Like what you hear?  Rate us on iTunes!  Chat with us on Twitter at <a href="https://twitter.com/roundstable" rel="nofollow" target="_blank">@roundstable</a> and tweet at Mike Nicholson <a href="https://twitter.com/doc_iron_mike" rel="nofollow" target="_blank">@doc_iron_mike</a>. Interested in helping us evaluate our podcast episodes? We’re currently recruiting a panel of residents to serve as regular reviewers for the show. If you’re interested, email <a href="mailto:wkwong@qmed.ca">wkwong@qmed.ca</a>. <h1>The Papers</h1> 1. Antibiotic Prophylaxis for IE: <a href="http://www.onlinejacc.org/content/72/20/2443" rel="nofollow" target="_blank">http://www.onlinejacc.org/content/72/20/2443</a> 2. Baloxavir Marboxil: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1716197" rel="nofollow" target="_blank">https://www.nejm.org/doi/full/10.1056/NEJMoa1716197</a> <h1>Good Stuff</h1> 1. Top Ten: <a href="https://www.liebertpub.com/doi/abs/10.1089/jpm.2018.0453?journalCode=jpm" rel="nofollow" target="_blank">https://www.liebertpub.com/doi/abs/10.1089/jpm.2018.0453?journalCode=jpm</a> 2. Cystic Fibrosis: <a href="https://www.cbc.ca/news/canada/london/cystic-fibrosis-patient-london-orkambi-1.4864042" rel="nofollow" target="_blank">https://www.cbc.ca/news/canada/london/cystic-fibrosis-patient-london-orkambi-1.4864042</a> <h1>Music Credits</h1> The Rounds Table Theme Music by Brendan Quinn, Creative Director and Composer, Vapor RMW The post <a href="https://healthydebate.ca/podcast/quit-buggin-me/" rel="nofollow" target="_blank">Quit Buggin’ Me: Antibiotic Prophylaxis for Infective Endocarditis and Baloxavir Marboxil for Uncomplicated Influenza</a> appeared first on <a href="https://healthydebate.ca" rel="nofollow" target="_blank">Healthy Debate</a>.

Quit Buggin’ Me: Antibiotic Prophylaxis for Infective Endocarditis and Baloxavir Marboxil for Uncomplicated Influenza